Jorgensen Nathan D. 4

What Happened

• Nathan D. Jorgensen, Chief Financial Officer of Voyager Therapeutics (VYGR), received equity awards on February 6, 2026: 32,250 restricted stock units (RSUs) and a derivative grant covering 150,500 shares in the form of stock options. Both grants were reported as acquisitions at $0.00 (typical for compensation awards) in the Form 4 filed on February 10, 2026. These are grants/awards (code A), not purchases or sales.

Key Details

• Transaction date: February 6, 2026; Form 4 filed: February 10, 2026 (appears to be filed one business day late relative to the SEC’s 2-business-day Form 4 deadline).
• RSUs: 32,250 RSUs; each unit converts to one share upon vesting. Vesting starts on the grant date and occurs over three years: 1/3 on the 1-year anniversary, then 1/3 each successive year (see footnote F1).
• Options (derivative): 150,500 share option grant. Vesting starts on the grant date and vests monthly over four years: 1/48th after one month, then monthly thereafter (see footnote F2). The filing lists no exercise price or cash exchanged in the grant entry.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• No tax-withholding sales, cashless exercises, 10b5-1 plans, or other sale transactions were reported in this filing.

Context

• These awards are standard executive compensation grants intended to retain and incentivize management; they do not represent an open-market purchase (a bullish signal) or a sale (a liquidity event). RSUs convert to common shares on vesting; options give the right to buy shares subject to exercise terms (exercise price not shown in the excerpt).